Medical algorithm: Diagnosis and treatment of hypereosinophilic syndrome

Barbara Schuster; Alexander Zink; Kilian Eyerich

doi:10.1111/all.14368

Medical algorithm: Diagnosis and treatment of hypereosinophilic syndrome

Barbara Schuster
, Alexander Zink
, Kilian Eyerich

Klinik und Poliklinik für Dermatologie und Allergologie

Publikation: Beitrag in Fachzeitschrift › Artikel › Begutachtung

12 Zitate (Scopus)

Originalsprache	Englisch
Seiten (von - bis)	3003-3006
Seitenumfang	4
Fachzeitschrift	Allergy: European Journal of Allergy and Clinical Immunology
Jahrgang	75
Ausgabenummer	11
DOIs	https://doi.org/10.1111/all.14368
Publikationsstatus	Veröffentlicht - 1 Nov. 2020

Zugriff auf Dokument

10.1111/all.14368

Andere Dateien und Links

Verknüpfung zur Publikation in Scopus

Dieses zitieren

@article{1dcbbe2c86c842a3b7f8cd09e8d9f136,

title = "Medical algorithm: Diagnosis and treatment of hypereosinophilic syndrome",

keywords = "allergy diagnosis, allergy treament, eosinophils, hypereosinophilic syndrome",

author = "Barbara Schuster and Alexander Zink and Kilian Eyerich",

note = "Funding Information: BS has received personal honoraria and grants from Novartis. A. Zink has been an advisor and/or received speaker's honoraria and/or received grants and/or participated in clinical trials of AbbVie, Amgen, lmirall, Beiersdorf Dermo Medical, Bencard Allergie, BMS, Celgene, Eli Lilly, GSK, Janssen Cilag, Miltenyi Biotec, Pfizer, Novartis, Sanofi‐Aventis, Takeda Pharma. KE is member or advisory boards and receives speaker´s fees from Abbvie, Almirall, BMS, Celgene, Hexal, Janssen, Novartis, Leo, Lilly, Sanofi, UCB.",

year = "2020",

month = nov,

day = "1",

doi = "10.1111/all.14368",

language = "English",

volume = "75",

pages = "3003--3006",

journal = "Allergy: European Journal of Allergy and Clinical Immunology",

issn = "0105-4538",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "11",

}

TY - JOUR

T1 - Medical algorithm

T2 - Diagnosis and treatment of hypereosinophilic syndrome

AU - Schuster, Barbara

AU - Zink, Alexander

AU - Eyerich, Kilian

N1 - Funding Information: BS has received personal honoraria and grants from Novartis. A. Zink has been an advisor and/or received speaker's honoraria and/or received grants and/or participated in clinical trials of AbbVie, Amgen, lmirall, Beiersdorf Dermo Medical, Bencard Allergie, BMS, Celgene, Eli Lilly, GSK, Janssen Cilag, Miltenyi Biotec, Pfizer, Novartis, Sanofi‐Aventis, Takeda Pharma. KE is member or advisory boards and receives speaker´s fees from Abbvie, Almirall, BMS, Celgene, Hexal, Janssen, Novartis, Leo, Lilly, Sanofi, UCB.

PY - 2020/11/1

Y1 - 2020/11/1

KW - allergy diagnosis

KW - allergy treament

KW - eosinophils

KW - hypereosinophilic syndrome

UR - https://www.scopus.com/pages/publications/85086231829

U2 - 10.1111/all.14368

DO - 10.1111/all.14368

M3 - Article

C2 - 32416612

AN - SCOPUS:85086231829

SN - 0105-4538

VL - 75

SP - 3003

EP - 3006

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

IS - 11

ER -